PCG
RETA

Private Capital Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Private Capital Group’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51
Closed -$2K – 2167
2022
Q1 		$2K Buy
+51
New +$1.51K ﹤0.01% 1852

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Private Capital Group's RETA Position: Q2 2022 in Review

Private Capital Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2022, closing a stake of 51 shares — an estimated $2K sold.

Private Capital Group first reported a position in RETA in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 146 funds tracked by Wall St. Rank hold RETA as of Q2 2022.

  • Private Capital Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • Private Capital Group sold 51 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2022, an estimated $2K.
  • Private Capital Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 1 quarter.
  • Private Capital Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2K in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.